Raymond James Financial Services Advisors, Inc. Athenex, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 08, 2023	BUY	$0.12 - $0.21 $1,284 - $2,247	10,700 New	10,700 $1,000

Others Institutions Holding ATNX

# of Institutions

Shares Held

1.46M

Call Options Held

Put Options Held

Empery Asset Management, LP New York, NY

1.45M
Shares

$14,521
2.33% of portfolio
Eaton Vance Management Boston, MA

12K
Shares

$120
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Athenex, Inc.

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

More about ATNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account